Citigroup Maintains Buy on ProKidney, Lowers Price Target to $8

Benzinga · 4d ago
Citigroup analyst Yigal Nochomovitz maintains ProKidney (NASDAQ:PROK) with a Buy and lowers the price target from $10 to $8.